Combining the articles mentioned:
Harrow Provides TRIESENCE Relaunch Update and Announces Investor Conference Participation
NASHVILLE, Tenn. - Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is elated to share a significant update on the relaunch of TRIESENCE (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that holds FDA approval for visualization during vitrectomy and the treatment of ocular inflammatory conditions resistant to current remedies. The successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches marks a significant milestone in Harrow’s commitment to delivering cutting-edge pharmaceutical solutions to the eyecare industry.
In addition to this update, Harrow is pleased to announce its participation in two prestigious investor conferences in May. The first conference is the B. Riley Securities 24th Annual Institutional Investor Conference, slated to be held at the Beverly Hilton Hotel in Beverly Hills, CA. During this event, Harrow’s management will engage in a Fireside Chat, followed by exclusive 1x1 investor meetings. The conference is scheduled to take place from Wednesday, May 22, 2024, to Thursday, May 23, 2024.
The second conference on Harrow’s agenda is the Craig-Hallum 21st Annual Institutional Investor Conference. Participating in this event further highlights Harrow’s commitment to actively engaging with the investment community. Harrow’s management will take part in various sessions and meetings to discuss the company’s latest advancements, strategies, and future plans.
In line with detailing its recent milestones, Harrow has also released its first-quarter financial results for the period ending March 31, 2024. The company’s strong performance during this quarter is a testament to its dedication to excellence in the eyecare pharmaceutical sector. Interested parties are encouraged to review the company’s first quarter Letter to Stockholders and corporate presentation, accessible on Harrow’s website, harrow.com. These documents provide stakeholders with valuable information regarding the company’s historical quarterly performance and its future growth prospects.
Harrow’s recent announcements reflect its continuous pursuit of innovation, commitment to shareholder engagement, and sustainable growth in the eyecare pharmaceutical industry. With its groundbreaking manufacturing achievement, upcoming participation in esteemed investor conferences, and promising financial results, Harrow continues to establish itself as a leading player in the evolving landscape of eyecare pharmaceuticals.
Comments